• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Bisphosphonates may reduce risk of endometrial cancer

byMonica ParksandDavid Wang
May 7, 2015
in Oncology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In a prospective cohort study of over 89 000 postmenopausal women, the use of bisphosphonates for osteoporosis was associated with a significant reduction in the risk of endometrial cancer.

Evidence Rating Level: 3 (Average)

Study Rundown: Although oral bisphosphonates are most commonly used for the treatment of osteoporosis among post-menopausal women, previous large prospective studies have demonstrated an associated between the use of bisphosphonates and cancer risk reduction. Previous results from the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial suggested an association between bisphosphonate use and endometrial cancer as well. The purpose of this study was to further investigate the potential protective effect of bisphosphonates in endometrial cancer. This study performed a secondary analysis of the Women’s Health Initiative Trial, which included a prospective cohort of over 89 000 post-menopausal women, for bisphosphonate use and follow-up endometrial cancer diagnoses. At the conclusion of this study, a history of ever use of bisphosphonates was associated with a moderate reduction in endometrial cancer risk, consistent with the findings of the PLCO trial. The results of this study support the hypothesis of a protective effect of bisphosphonates in endometrial cancer. The strengths of this study include the large population size. However, the study is limited by its observational design, which makes it difficult to control for important confounders such as low endogenous estrogen level resulting in both high fracture risk and lower risk of endometrial cancer. Additional randomized controlled trials are required to fully elucidate this relationship.

Click to read the study in the JCO (Journal of Clinical Oncology)

Relevant Reading: Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial

In-Depth [prospective cohort]: This study was a secondary analysis of 89 918 postmenopausal women enrolled in the Women’s Health Initiative (WHI) prospective cohort. WHI collected enrolled over    160 000 women aged 50-79 from over 40 clinical sites across the United States from 1993 to 1998. All women had an intact uterus upon enrollment; exclusion criteria included patients with a history of endometrial or breast cancer, hysterectomy, anti-estrogen use, or hormone therapy for bone fracture. The primary outcomes were bisphosphonate use and incidence of invasive endometrial cancer. Outcomes were determined from a detailed health interview at intake, and determined bisphosphonate use from medication inventories at baseline and at 1, 3, and 6 years follow-up. Patients were considered bisphosphonate ever-users if they had reported use for at least 2 weeks in duration. After a median follow-up was 12.5 years, bisphosphonate use ranged from 2% at the start of the study to 10% by year 6. A total of 1123 women developed endometrial cancer over this time period. Bisphosphonate ever-users were associated with a significantly reduced risk of endometrial cancer (HR: 0.80; 95% CI: 0.64-1.00, p = 0.05). Hazard ratios did not vary significantly with duration of use. There were no significant interactions with patient BMI (p = 0.41), age at the start of the study (p = 0.21) or hip fracture probability score (p = 0.83).

RELATED REPORTS

Sacituzumab tirumotecan improved progression-free and overall survival versus chemotherapy in previously treated endometrial cancer

Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bisphosphonatesendometrial cancer
Previous Post

Study finds variation in treatment of extremely pre-term infants among hospitals

Next Post

Ultrasound-guided cryoablation shows promise in treating ductal carcinomas

RelatedReports

The image illustrates antibodies and a pill, representing immunotherapy and steroid treatments in oncology, with visual elements suggesting timing of administration.
2MM Trial Briefs

Sacituzumab tirumotecan improved progression-free and overall survival versus chemotherapy in previously treated endometrial cancer

October 29, 2026
Weight-loss medicines and endometrial cancer collage: an engraved uterus with tubes and ovaries, an injection pen, a magnolia
Endocrinology

Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia

February 16, 2026
Weekly research roundup collage: a young man in glasses and a crewneck sweater beside a stack of blank books and a coffee cup
Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
Chronic Disease

The Scan by 2 Minute Medicine®: Daily caffeine intake linked to lower dementia risk, AAP sues over federal vaccine schedule overhaul, Catherine O’Hara passes away after short illness, and GLP-1 receptor agonists reduce endometrial cancer risk

February 11, 2026
Next Post
Ultrasound-guided cryoablation shows promise in treating ductal carcinomas

Ultrasound-guided cryoablation shows promise in treating ductal carcinomas

Quantitative susceptibility mapping may help diagnose amyotrophic lateral sclerosis

MRI study characterizes breast cancer patterns in augmented breasts

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.